VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Camidge Discusses Next-Generation Sequencing

D. Ross Camidge, MD, PhD
Published: Thursday, Oct 24, 2013

D. Ross Camidge, MD, PhD, the director of the Thoracic Oncology Clinical Program at the University of Colorado Cancer Center, explains excitement over the potential role for next-generation sequencing in cancer care.

Next-generation sequencing, or massively parallel sequencing, provides a focused platform for sequencing 300 to 400 genes from a single sample. This approach supplies an opportunity to not only check for common mutations but also rare alterations, Camidge notes.

At this point, several companies have developed next-generation sequencing platforms. These technologies allow for the detection of several mutations that can be customized based on the tumor type, such as EGFR, ALK, and ROS1 in lung cancer. Next-generation sequencing removes confusion over which genes need sequenced, especially as new mutations are rapidly discovered, Camidge suggests.

If several tests are required, the cost associated with individually testing—both financially and in regard to the tumor samples—becomes prohibitive after 4-5 tests. The cost for next-generation sequencing is still at $5000, Camidge states. However, in the next 3 years, Camidge predicts that the cost associated with this approach will continue to decline, making it a viable option in the community setting.

D. Ross Camidge, MD, PhD, the director of the Thoracic Oncology Clinical Program at the University of Colorado Cancer Center, explains excitement over the potential role for next-generation sequencing in cancer care.

Next-generation sequencing, or massively parallel sequencing, provides a focused platform for sequencing 300 to 400 genes from a single sample. This approach supplies an opportunity to not only check for common mutations but also rare alterations, Camidge notes.

At this point, several companies have developed next-generation sequencing platforms. These technologies allow for the detection of several mutations that can be customized based on the tumor type, such as EGFR, ALK, and ROS1 in lung cancer. Next-generation sequencing removes confusion over which genes need sequenced, especially as new mutations are rapidly discovered, Camidge suggests.

If several tests are required, the cost associated with individually testing—both financially and in regard to the tumor samples—becomes prohibitive after 4-5 tests. The cost for next-generation sequencing is still at $5000, Camidge states. However, in the next 3 years, Camidge predicts that the cost associated with this approach will continue to decline, making it a viable option in the community setting.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x